Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer

Purpose Surgical cytoreduction remains a cornerstone in the management of patients with advanced and recurrent epithelial ovarian cancer. Parenchymal liver metastases determine stage VI disease and are commonly considered a major limit in the achievement of an optimal cytoreduction. The purpose of t...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2016-07, Vol.142 (7), p.1509-1520
Main Authors: Gasparri, Maria Luisa, Grandi, Giovanni, Bolla, Daniele, Gloor, Beat, Imboden, Sara, Panici, Pierluigi Benedetti, Mueller, Michael D., Papadia, Andrea
Format: Article
Language:English
Subjects:
Cancer Research
Cancer surgery
Carcinoma, Ovarian Epithelial
Female
Hematology
Humans
Internal Medicine
Liver
Liver Neoplasms - secondary
Liver Neoplasms - surgery
Medicine
Medicine & Public Health
Metastasis
Neoplasms, Glandular and Epithelial - pathology
Neoplasms, Glandular and Epithelial - surgery
Oncology
Ovarian cancer
Ovarian Neoplasms - pathology
Ovarian Neoplasms - surgery
Recurrence
Review – Clinical Oncology
Surgical outcomes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Surgical cytoreduction remains a cornerstone in the management of patients with advanced and recurrent epithelial ovarian cancer. Parenchymal liver metastases determine stage VI disease and are commonly considered a major limit in the achievement of an optimal cytoreduction. The purpose of this manuscript was to discuss the rationale of liver resection and the morbidity related to this procedure in advanced and recurrent ovarian cancer. Methods A search of the National Library of Medicine’s MEDLINE/PubMed database until March 2015 was performed using the keywords: “ovarian cancer,” “hepatic,” “liver,” and “metastases.” Results In patients with liver metastases, hepatic resection is associated with a similar prognosis as stage IIIC patients. The length of the disease-free interval between primary diagnosis and occurrence of liver metastases, as well as residual disease after resection, is the most important prognostic factors. In addition, the number of liver lesions, resection margins, and the gynecologic oncology group performance status seem to play also an important role in determining outcome. Conclusions In properly selected patients, liver resections at the time of cytoreduction increase rates of optimal cytoreduction and improve survival in advanced-stage and recurrent ovarian cancer patients.
ISSN:0171-5216
1432-1335
DOI:10.1007/s00432-015-2090-3